Key interrelated indicators, including ALT, MetS, gut microbiota, oxidative stress, and adipose tissue inflammation, strongly associated with both MASLD/NAFLD and CVD, should be integrated into cardiovascular risk screening protocols. The gene discussed is GPT; the disease is metabolic syndrome.